After reading these articles, you should be able to…

There is a high demand for psychiatric care in U.S. correctional facilities. At any given time, about 1% of the adult population is incarcerated, and many of them have a psychiatric disorder of some sort.

The average annual wage for U.S. psychiatrists in 2015 is about $194,000 (U.S. Bureau of Labor Statistics). According to a 2011 salary survey, the average salary of a prison psychiatrist in the U.S. is $204,909. And these averages are probably on the low side.

Dr. Patrick Gariety shares his experiences as a treatment clinician working in a facility with about 300 psychiatric patients, staffed with five psychiatrists and eight psychologists. The psychiatric population was extremely mixed, with most of the patients suffering from some form of chronic mental illness, and/or severe personality disorders.

Electroconvulsive therapy (ECT) is well known to cause short-term amnesia and disorientation around the time of treatment. However, for most of our patients, these cognitive side effects improve and disappear fairly quickly, usually within a few days. We have less information about how long-term ECT may affect our patients, such as those who have had multiple courses over the years, or those who have undergone maintenance monthly treatments. A recent study provides us with some reassuring data.

Second-generation antipsychotics (SGA) are used for a variety of psychiatric conditions, but even though they’ve been around for 20 years, we know little about what impact they have on the developing fetus. These medications are widely considered to be relatively safe during pregnancy, but this assumption is based on scant evidence. In this paper, researchers tapped into the Massachusetts General Hospital (MGH) National Pregnancy Registry of Atypical Antipsychotics and reported some reassuring results.

...

Since 2011, 3 new antidepressants have been approved by the FDA, and another (ketamine) has been generating buzz as a potential off-label medication for depression. In this article, we’ll take a step back and review the data on vilazodone (Viibryd), levomilnacipran (Fetzima), vortioxetine (Brintellix), and ketamine.

Dr. Bodkin discusses methods for approaching treatment resistant depression and his perspective on depressive illness as a final common pathway for a number of different brain problems.

Once you have read the issue, you can take this post-test to earn CME credit.